Biochips (microarrays/Microfludics) Global Market - Forecast to 2023

Publishing Date : June, 2017
Report Code : HCBT0104
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Biochips come handy as thousands of experiments are performed on a small chip with a solid platform and acts like a mini laboratory. Usage of biochips has increased in the past decade as its application varies from high throughput screening in drug discovery to personalized medicine.

The global biochips market is expected to grow at double digit CAGR to reach $17,851.1 million by 2023. Biochips market is mainly classified into technologies, products, application and end-users. The global biochips market is broadly classified as micro arrays and microfluidics based on technology. Based on products, the market is classified into Instruments, Reagents & Consumables and Software & Services. Biochips market is segmented on the basis of application as Genomics, Proteomics, Drug discovery, Diagnostics, Food & agricultural testing and others. Genomics application segment is further classified into SNP Genotyping, Gene Expression and Others where as Drug discovery segment is further sub segmented into Target Identification & Validation, HTS (High Throughput screening) and Lead Optimization. Diagnostics segment is further divided into Cancer diagnostics and other diagnostics. End-Users are further classified into Pharmaceutical & Biotech companies, Academic & Research laboratories, Diagnostic laboratories, CROs (Contract and Research Organizations) and others.

Among microarrays and Microfluidics, Microfluidics occupies the major share in 2016 and is expected to grow at a highest CAGR from 2016 to 2023. Among products Reagents & consumables occupy the major share of XX% in 2016 and are expected to grow at a CAGR of XX% from 2016 to 2023 to reach $XX million by 2023. Among Application segment Diagnostics commanded the larger revenue in 2016 and is expected to grow at a highest CAGR of XX% from 2016 to 2023. Among Genomics, SNP genotyping occupies a major share in 2016 with a CAGR of XX% from 2016 to 2023. Target Identification & Validation in Drug discovery segment occupies a major share of XX% in 2016 and similarly other diagnostics occupies a major share of XX% in 2016 and grows with a CAGR of XX% from 2016 to 2023. Diagnostic laboratories occupy a major share of XX% in 2016 and grow with a maximum CAGR of XX% from 2016 to 2023.

Revolution in the field of genomics, proteomics as well as rapid drug discovery increased the demand for biochips. In addition, increase in diagnosis and treatment of cancer and genetic diseases, approval for personalized medicines and invention of novel technologies in biochips drives the market of biochips. Standardization and quality assurance of biochips, technological ease in handling the biochips especially in the areas of diagnosis and treatment, high cost along with ethical and social issues hinders the market growth.

Lifestyle changes owing to increase in cancer, diabetes and hypertension patients, early diagnosis and treatment of diseases, advancement of biochips with its wide application areas shows that biochip market has vast opportunities in the coming years.

North America accounts for the highest market share in 2016 and followed by Europe. Steep rise in genetic diagnosis, huge corporate outsourcing for drug discovery, increase in personalized medicines and favourable government policies makes U.S. the leader of Biochips market. However, Asian countries especially China and Japan are the fastest growing regions with its growing demand for biochips and increasing research investments. Asia-Pacific grows with a highest CAGR of XX% from 2016 to 2023.

Major players in biochips market include Abbott laboratories (U.S.), Agilent Technologies (U.S.), Becton-Dickinson Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Fluidigm Corporation (U.S.), GE Healthcare (U.S.), Illumina (U.S.), PerkinElmer, Inc. (U.S.) and Thermo Fisher Scientific, Inc. (U.S.).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASE IN USAGE OF BIOCHIPS IN CANCER DIAGNOSTICS
        • 3.3.1.2     BIOCHIPS PREFERENCE IN PERSONALIZED MEDICINE
        • 3.3.1.3     WIDENING APPLICATION MARKET
        • 3.3.1.4     EMERGING ASIA PACIFIC MARKET
        • 3.3.1.5     INCREASED GOVERNMENT FUNDING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH COST OF BIOCHIPS
        • 3.3.2.2     LACK OF STANDARDIZATION
        • 3.3.2.3     LIMITED SKILLED PERSONNEL TO WORK ON BIOCHIPS
        • 3.3.2.4     STRINGENT REGULATIONS
        • 3.3.2.5     ADOPTION OF NGS
    • 3.4     PORTER’S FIVE FORCE ANALYSIS
      • 3.4.1     THREAT OF NEW ENTRANTS
      • 3.4.2     THREAT OF SUBSTITUTES
      • 3.4.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.4.4     BARGAINING POWER OF SUPPLIERS
      • 3.4.5     BARGAINING POWER OF BUYERS
    • 3.5     REGULATORY GUIDELINES
      • 3.5.1     UNITED STATES
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
    • 3.6     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.6.1     MICROARRAY TECHNOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.6.2     MICROFLUIDIC TECHNOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS
    • 3.7     PATENT TRENDS
    • 3.8     SUPPLY CHAIN ANALYSIS
    • 3.9     BIOCHIPS UNDER CLINICAL TRIAL
    • 3.10     NEW PRODUCT LAUNCHES
    • 3.11     TECHNOLOGICAL ADVANCEMENTS
      • 3.11.1     “LAB ON A CHIP’ THAT COSTS 1 CENT TO MAKE
      • 3.11.2     LIGHT BASED LAB-ON-A-CHIP DEVICE
      • 3.11.3     NEW NEURO CHIP
      • 3.11.4     3D PRINTED ORGAN-ON-A-CHIP
      • 3.11.5     LIQUID BIOPSY CHIPS FOR THE DETECTION OF METASTATIC CANCER CELLS
      • 3.11.6     PLACENTA ON A CHIP
  • 4     BIOCHIPS GLOBAL MARKET, BY TECHNOLOGY
    • 4.1     INTRODUCTION
    • 4.2     MICROARRAYS
      • 4.2.1     DNA MICROARRAYS
      • 4.2.2     PROTEIN MICROARRAYS
      • 4.2.3     TISSUE MICROARRAYS
      • 4.2.4     CELL MICROARRAYS
      • 4.2.5     OTHER MICROARRAYS
    • 4.3     LAB-ON-A-CHIP (MICROFLUIDICS)
      • 4.3.1     PCR-ON-A-CHIP
      • 4.3.2     IMMUNOASSAYS-ON-A-CHIP
      • 4.3.3     ELECTROPHORESIS-ON-A-CHIP
      • 4.3.4     FLOW CYTOMETRY-ON-A-CHIP
      • 4.3.5     NGS-ON-A-CHIP
      • 4.3.6     ORGAN-ON-CHIP
      • 4.3.7     OTHERS
  • 5     BIOCHIPS GLOBAL MARKET, BY PRODUCTS
    • 5.1     INTRODUCTION
    • 5.2     INSTRUMENTS
    • 5.3     REAGENTS AND CONSUMABLES
    • 5.4     SOFTWARE AND SERVICES
  • 6     BIOCHIPS GLOBAL MARKET, BY APPLICATIONS
    • 6.1     INTRODUCTION
    • 6.2     GENOMICS
      • 6.2.1     GENE EXPRESSION
      • 6.2.2     SNP GENOTYPING
      • 6.2.3     OTHER GENOMICS
    • 6.3     PROTEOMICS
    • 6.4     DRUG DISCOVERY & DEVELOPMENT
      • 6.4.1     TARGET IDENTIFICATION AND VALIDATION
      • 6.4.2     HIGH THROUGHPUT SCREENING
      • 6.4.3     LEAD OPTIMIZATION
    • 6.5     DIAGNOSTICS
      • 6.5.1     CANCER DIAGNOSTICS
      • 6.5.2     OTHER DIAGNOSTICS
    • 6.6     FOOD AND AGRICULTURE TESTING
    • 6.7     OTHERS
  • 7     BIOCHIPS GLOBAL MARKET, BY END-USERS
    • 7.1     INTRODUCTION
    • 7.2     PHARMACEUTICAL AND BIOTECH COMPANIES
    • 7.3     ACADEMIC & RESEARCH LABORATORIES
    • 7.4     CONTRACT RESEARCH ORGANISATIONS
    • 7.5     DIAGNOSTIC LABORATORIES
    • 7.6     OTHERS
  • 8     REGIONAL MARKET ANALYSIS
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     OTHERS
    • 8.3     EUROPE
      • 8.3.1     GERMANY
      • 8.3.2     U.K.
      • 8.3.3     FRANCE
      • 8.3.4     OTHERS
    • 8.4     ASIA-PACIFIC
      • 8.4.1     CHINA
      • 8.4.2     JAPAN
      • 8.4.3     INDIA
      • 8.4.4     OTHERS
    • 8.5     REST OF THE WORLD
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF LATIN AMERICA
      • 8.5.3     MIDDLE EAST AND OTHERS
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
    • 9.2     NEW PRODUCT LAUNCHES
    • 9.3     AGREEMENTS, PARTNERSHIP, COLLABORATION & JOINT VENTURES
    • 9.4     APPROVALS
    • 9.5     MERGERS & ACQUISITIONS
    • 9.6     OTHER DEVELOPMENTS
  • 10     MAJOR COMPANIES
    • 10.1     ABBOTT LABORATORIES
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     AGILENT TECHNOLOGIES, INC.
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     BECTON DICKINSON AND COMPANY
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     BIO-RAD LABORATORIES
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     DANAHER CORPORATION
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     FLUIDIGM CORPORATION
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     GE HEALTHCARE
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     ILLUMINA, INC.
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     PERKINELMER, INC.
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     THERMOFISHER SCIENTIFIC INC.
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     BIOCHIPS GLOBAL MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 2     BIOCHIPS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2015-2023)($MN)
      • TABLE 3     BIOCHIPS GLOBAL MARKET REVENUE, BY PRODUCT, (2015-2023)($MN)
      • TABLE 4     BIOCHIPS GLOBAL MARKET REVENUE, BY APPLICATION (2015-2023)($MN)
      • TABLE 5     BIOCHIPS GLOBAL MARKET REVENUE, BY END USERS (2015-2023)($MN)
      • TABLE 6     BIOCHIPS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2015-2023)($MN)
      • TABLE 7     MICROARRAYS GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 8     MICROARRAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2015-2023)($MN)
      • TABLE 9     DNA MICROARRAYS GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 10     PROTEIN MICROARRAYS GLOBAL MARKET REVENUE,BY REGION (2015-2023) ($MN)
      • TABLE 11     TISSUE MICROARRAYS GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 12     CELL MICROARRAYS GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 13     OTHER MICROARRAYS GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 14     MICROFLUIDIC GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 15     MICROFLUIDICS GLOBAL MARKET REVENUE,BY TECHNOLOGY TYPE (2015-2023)($MN)
      • TABLE 16     PCR-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 17     IMMUNOASSAYS-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 18     ELECTROPHORESIS-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 19     FLOW CYTOMETRY-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 20     NGS-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 21     ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 22     OTHERS LAB-ON-A-CHIP GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 23     BIOCHIPS GLOBAL MARKET REVENUE,BY PRODUCTS, (2015-2023)($MN)
      • TABLE 24     INSTRUMENTS BIOCHIPS GLOBAL MARKET REVENUE,BY REGION, (2015-2023)($MN)
      • TABLE 25     REAGENTS AND CONSUMABLES BIOCHIPS GLOBAL MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 26     SOFTWARE & SERVICES BIOCHIPS GLOBAL MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 27     BIOCHIPS GLOBAL MARKET REVENUE, BY APPLICATIONS, (2015-2023)($MN)
      • TABLE 28     GENOMICS BIOCHIPS GLOBAL MARKET REVENUE,BY REGION, (2015-2023)($MN)
      • TABLE 29     GENOMICS BIOCHIPS GLOBAL MARKET REVENUE,BY TYPE (2015-2023)($MN)
      • TABLE 30     GENE EXPRESSION BIOCHIPS GLOBAL MARKET REVENUE,BY REGION, (2015-2023)($MN)
      • TABLE 31     SNP GENOTYPING BIOCHIPS GLOBAL MARKET REVENUE,BY REGION (2015-2023)($MN)
      • TABLE 32     OTHERS GENOMICS BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 33     PROTEOMICS BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 34     DRUG DISCOVERY BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 35     DRUG DISCOVERY BIOCHIPS GLOBAL MARKET REVENUE, BY TYPE (2015-2023)($MN)
      • TABLE 36     TARGET IDENTIFICATION & VALIDATION BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 37     HIGH THROUGHPUT SCREENING BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 38     LEAD OPTIMIZATION BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 39     DIAGNOSTICS BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 40     DIAGNOSTICS BIOCHIPS GLOBAL MARKET REVENUE, BY TYPE (2015-2023)($MN)
      • TABLE 41     CANCER DIAGNOSTICS BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 42     OTHER DIAGNOSTICS BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 43     FOOD & AGRICULTURE TESTING BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 44     OTHER APPLICATIONS BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023)($MN)
      • TABLE 45     BIOCHIPS GLOBAL MARKET REVENUE, BY END-USER, (2015-2023)($MN)
      • TABLE 46     PHARMACEUTICAL & BIOTECH COMPANIES BIOCHIPS GLOBAL END USERS MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 47     ACADEMIC & RESEARCH LABORATORIES BIOCHIPS GLOBAL END USERS MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 48     CRO’S BIOCHIPS GLOBAL END USERS MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 49     DIAGNOSTIC LABORATORIES BIOCHIPS GLOBAL END USERS MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 50     OTHERS BIOCHIPS GLOBAL END USERS MARKET REVENUE, BY REGION, (2015-2023)($MN)
      • TABLE 51     NORTH AMERICAN BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, (2015-2023)($MN)
      • TABLE 52     NORTH AMERICAN MICROARRAYS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 53     NORTH AMERICAN MICROFLUIDICS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 54     NORTH AMERICAN BIOCHIPS MARKET REVENUE, BY PRODUCTS (2015-2023)($MN)
      • TABLE 55     NORTH AMERICAN BIOCHIPS MARKET REVENUE,BY APPLICATION, (2015-2023)($MN)
      • TABLE 56     NORTH AMERICAN GENOMICS BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 57     NORTH AMERICAN DRUG DISCOVERY BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 58     NORTH AMERICAN DIAGNOSTICS BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 59     NORTH AMERICAN BIOCHIPS MARKET REVENUE,BY END-USERS, (2015-2023)($MN)
      • TABLE 60     EUROPEAN BIOCHIPS MARKET REVENUE,BY TECHNOLOGY, (2015-2023)($MN)
      • TABLE 61     EUROPEAN MICROARRAYS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 62     EUROPEAN MICROFLUIDICS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 63     EUROPEAN BIOCHIPS MARKET REVENUE,BY PRODUCTS (2015-2023)($MN)
      • TABLE 64     EUROPEAN BIOCHIPS MARKET REVENUE,BY APPLICATION, (2015-2023)($MN)
      • TABLE 65     EUROPEAN GENOMICS BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 66     EUROPEAN DRUG DISCOVERY BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 67     EUROPEAN DIAGNOSTICS BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 68     EUROPEAN BIOCHIPS MARKET REVENUE,BY ENDUSERS, (2015-2023)($MN)
      • TABLE 69     ASIA PACIFIC BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023)($MN)
      • TABLE 70     ASIA PACIFIC MICROARRAYS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 71     ASIA PACIFIC MICROFLUIDICS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 72     ASIA PACIFIC BIOCHIPS MARKET REVENUE,BY PRODUCTS (2015-2023)($MN)
      • TABLE 73     ASIA PACIFIC BIOCHIPS MARKET REVENUE,BY APPLICATION, (2015-2023)($MN)
      • TABLE 74     ASIA PACIFIC GENOMICS BIOCHIPS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 75     ASIA PACIFIC DRUG DISCOVERY BIOCHIPS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 76     ASIA PACIFIC DIAGNOSTICS BIOCHIPS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 77     ASIA PACIFIC BIOCHIPS MARKET REVENUE,BY ENDUSERS, (2015-2023) ($MN)
      • TABLE 78     ROW BIOCHIPS MARKET REVENUE, BY TYPE, (2015-2023) ($MN)
      • TABLE 79     ROW MICROARRAYS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 80     ROW MICROFLUIDICS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 81     ROW BIOCHIPS MARKET REVENUE,BY PRODUCTS (2015-2023)($MN)
      • TABLE 82     ROW BIOCHIPS MARKET REVENUE,BY APPLICATION, (2015-2023)($MN)
      • TABLE 83     ROW GENOMICS BIOCHIPS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 84     ROW DRUG DISCOVERY BIOCHIPS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 85     ROW DIAGNOSTICS BIOCHIPS MARKET REVENUE,BY TYPE, (2015-2023)($MN)
      • TABLE 86     ROW BIOCHIPS MARKET REVENUE,BY ENDUSERS, (2015-2023)($MN)
      • TABLE 87     NEW PRODUCT LAUNCHES (2015-2017)
      • TABLE 88     AGREEMENTS, PARTNERSHIP, COLLABORATION & JOINT VENTURES (2015-2017)
      • TABLE 89     APPROVALS (2015-2017)
      • TABLE 90     MERGERS & ACQUISITIONS (2015-2017)
      • TABLE 91     OTHER DEVELOPMENTS (2014-2016)
      • TABLE 92     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016)($MN)
      • TABLE 93     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016)($MN)
      • TABLE 94     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 95     AGILENT TECHNOLOGIES: TOTAL REVENUE AND R&D EXPENSES (2014-2016)($MN)
      • TABLE 96     AGILENT TECHNOLOGIES: TOTAL REVENUE,BY SEGMENTS, (2014-2016)($MN)
      • TABLE 97     AGILENT TECHNOLOGIES: TOTAL REVENUE,BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 98     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2014-2016)($MN)
      • TABLE 99     BECTON DICKINSON AND COMPANY: TOTAL REVENUE,BY SEGMENTS, (2014-2016)($MN)
      • TABLE 100     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFE SCIENCE SEGMENTS, (2014-2016)($MN)
      • TABLE 101     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 102     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2014-2016)($MN)
      • TABLE 103     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016)($MN)
      • TABLE 104     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 105     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016)($MN)
      • TABLE 106     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016)($MN)
      • TABLE 107     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 108     FLUIDIGM CORPORATION: OPERATIONAL REVENUE AND R&D EXPENSES (2014-2016)($MN)
      • TABLE 109     FLUIDIGM CORPORATION: TOTAL REVENUE,BY SEGMENTS, (2014-2016)($MN)
      • TABLE 110     FLUIDIGM CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 111     GE HEALTHCARE: TOTAL REVENUE AND R&D EXPENSES, (2014-2016)($MN)
      • TABLE 112     GENERAL ELECTRIC COMPANY : TOTAL REVENUE, BY SEGMENTS (2014-2016)($MN)
      • TABLE 113     GENERAL ELECTRIC COMPANY : TOTAL REVENUE, BY GEOGRAPHY (2014-2016)($MN)
      • TABLE 114     ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2014-2016)($MN)
      • TABLE 115     ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY,(2014-2016)($MN)
      • TABLE 116     PERKINELMER, INC.: TOTAL REVENUE AND R&D EXPENSES (2014-2016)($MN)
      • TABLE 117     PERKINELMER, INC.: TOTAL REVENUE,BY SEGMENTS, (2014-2016)($MN)
      • TABLE 118     PERKINELMER, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)
      • TABLE 119     THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016)($MN)
      • TABLE 120     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016)($MN)
      • TABLE 121     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016)($MN)

      LIST OF FIGURES

      • FIGURE 1     BIOCHIPS GLOBAL MARKET SHARE AND REVENUE, BY REGION (2015-2023)
      • FIGURE 2     RESEARCH METHODOLOGY: BIOCHIPS GLOBAL MARKET
      • FIGURE 3     BIOCHIPS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     BIOCHIPS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     BIOCHIPS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     BIOCHIPS GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     BIOCHIPS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     BIOCHIPS GLOBAL MARKET SHARE ANALYSIS,
      • FIGURE 10     MICROARRAYS GLOBAL MARKET SHARE ANALYSIS,
      • FIGURE 11     MICROFLUIDICS GLOBAL MARKET SHARE ANALYSIS,
      • FIGURE 12     BIOCHIPS GLOBAL MARKET: PCT PATENT FILING BY MAJOR PLAYERS (2012-2017)
      • FIGURE 13     BIOCHIPS GLOBAL MARKET SHARE, BY TECHNOLOGY (2016 V’S 2023) (%)
      • FIGURE 14     BIOCHIPS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPES (2016)
      • FIGURE 15     BIOCHIPS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPES (2016)
      • FIGURE 16     BIOCHIPS GLOBAL MARKET REVENUE, BY PRODUCTS (2016 V’S 2023)
      • FIGURE 17     BIOCHIPS GLOBAL MARKET REVENUE, BY APPLICATIONS (2016 V’S 2023)
      • FIGURE 18     BIOCHIPS GENOMICS, DIAGNOSTICS & DRUG DISCOVERY GLOBAL MARKET REVENUE, BY APPLICATION TYPE (2016 V’S 2023)
      • FIGURE 19     BIOCHIPS GLOBAL MARKET SHARE, BY END-USERS (2016 V’S 2023)
      • FIGURE 20     BIOCHIPS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN) CAGR (%)
      • FIGURE 21     NORTH AMERICAN BIOCHIPS MARKET REVENUE, BY TECHNOLOGY & PRODUCTS (2016 V’S 2023) ($MN)
      • FIGURE 22     NORTH AMERICAN MICROARRAYS & MICROFLUIDICS MARKET REVENUE, BY TYPES (2016 V’S 2023) ($MN)
      • FIGURE 23     NORTH AMERICAN BIOCHIPS MARKET REVENUE, BY APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 24     NORTH AMERICAN BIOCHIPS APPLICATION MARKET REVENUE, BY TYPES (2016 V’S 2023) ($MN)
      • FIGURE 25     NORTH AMERICAN BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 26     UNITED STATES BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 27     UNITED STATES BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 28     OTHER NORTH AMERICAN REGIONS BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 29     OTHER NORTH AMERICAN REGIONS BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 30     EUROPEAN BIOCHIPS MARKET REVENUE, BY TECHNOLOGY & PRODUCTS (2016 V’S 2023) ($MN)
      • FIGURE 31     EUROPEAN MICROARRAYS AND MICROFLUIDICS MARKET REVENUE, BY TYPES (2016 V’S 2023) ($MN)
      • FIGURE 32     EUROPEAN BIOCHIPS MARKET REVENUE, BY APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 33     EUROPEAN BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE (2016 V’S 2023) ($MN)
      • FIGURE 34     EUROPEAN BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 35     GERMANY BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 36     GERMANY BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 37     U.K. BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 38     U.K. BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 39     FRANCE BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 40     FRANCE BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 41     OTHER EUROPEAN REGIONS BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 42     OTHER EUROPEAN REGIONS BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 43     ASIA-PACIFIC BIOCHIPS MARKET REVENUE, BY TECHNOLOGY & PRODUCTS (2016 V’S 2023) ($MN)
      • FIGURE 44     ASIA-PACIFIC MICROARRAYS AND MICROFLUIDICS MARKET REVENUE, BY TYPE (2016 V’S 2023) ($MN)
      • FIGURE 45     ASIA-PACIFIC BIOCHIPS MARKET REVENUE, BY APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 46     ASIA-PACIFIC BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE (2016 V’S 2023) ($MN)
      • FIGURE 47     ASIA-PACIFIC BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 48     CHINA BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 49     CHINA BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 50     JAPAN BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 51     JAPAN BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 52     INDIA BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 53     INDIA BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 54     OTHER ASIA PACIFIC REGIONS BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 55     OTHER ASIA PACIFIC REGIONS BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 56     ROW BIOCHIPS MARKET REVENUE, BY TECHNOLOGY & PRODUCTS (2016 V’S 2023) ($MN)
      • FIGURE 57     ROW MICROARRAY & MICROFLUIDICS MARKET REVENUE, BY TYPE (2016 V’S 2023) ($MN)
      • FIGURE 58     ROW BIOCHIPS MARKET REVENUE, BY APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 59     ROW BIOCHIPS APPLICATION MARKET REVENUE, BY TYPE (2016 V’S 2023) ($MN)
      • FIGURE 60     ROW BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 61     BRAZIL BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 62     BRAZIL BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 63     REST OF LATIN AMERICA BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 64     REST OF LATIN AMERICA BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 65     MIDDLE EAST AND OTHERS BIOCHIPS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS & APPLICATIONS (2016 V’S 2023) ($MN)
      • FIGURE 66     MIDDLE EAST AND OTHERS BIOCHIPS MARKET REVENUE, BY END-USERS (2016 V’S 2023) ($MN)
      • FIGURE 67     KEY GROWTH STRATEGIES, (2015 – 2017)
      • FIGURE 68     SWOT: ABBOTT LABORATORIES
      • FIGURE 69     SWOT: AGILENT TECHNOLOGIES
      • FIGURE 70     SWOT: BECTON DICKINSON AND COMPANY
      • FIGURE 71     SWOT: BIORAD LABORATORIES
      • FIGURE 72     SWOT: DANAHER CORPORATION
      • FIGURE 73     SWOT: FLUIDIGM CORPORATION
      • FIGURE 74     SWOT: GE HEALTHCARE
      • FIGURE 75     SWOT: ILLUMINA, INC.
      • FIGURE 76     SWOT: PERKINELMER, INC.
      • FIGURE 77     SWOT: THERMOFISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABAXIS
      • 2     ABBOTT LABORATORIES
      • 3     ABCAM
      • 4     ABNOVA CORPORATION
      • 5     ACHIRA LABS PVT. LTD
      • 6     ACUROS
      • 7     ADVALYTIX AG
      • 8     ADVANCED MICROLAB
      • 9     ADVION
      • 10     AGILENT TECHNOLOGIES
      • 11     AKCELI
      • 12     AKONNI BIOSYSTEMS
      • 13     ALINE INC
      • 14     ARRAY JET
      • 15     ARRAYIT CORPORATION
      • 16     ASTERAND BIOSCIENCES
      • 17     AUSHON BIOSYSTEMS
      • 18     AXXICON HOLDINGS BV
      • 19     AYOXA BIOSYSTEMS
      • 20     BAEBIES
      • 21     BARTELS MIKROTECHNIK
      • 22     BECTON DICKINSON & COMPANY
      • 23     BIFLOW SYSTEMS GERMANY
      • 24     BIOCAT
      • 25     BIOCHAIN
      • 26     BIOGENEX
      • 27     BIOMETRIX TECHNOLOGY,INC
      • 28     BIONAS GMBH
      • 29     BIONEER CORPORATION
      • 30     BIO-RAD LABORATORIES
      • 31     BIOTRAY
      • 32     CAMBRIDGE PROTEIN ARRAYS LIMITED
      • 33     CAMBRIDGE BIOMAGNETICSLTD.
      • 34     CAPITAL BIOTECHNOLOGY CO. LIMITED
      • 35     CELL SIGNALLING TECHNOLOGY INC.
      • 36     CELLIX
      • 37     CETONI
      • 38     CHROMA VISION MEDICAL SYSTEMS, INC
      • 39     CIPHERGEN BIOSYSTEMS
      • 40     CLEARBRIDGE BIOMEDICS
      • 41     CLONTECH LABORATORIES, INC (TAKARA BIO)
      • 42     COMBIMATRIX CORPORATION
      • 43     CREATIVE MICROSYSTEMS CORPORATION
      • 44     CYCLOFLUIDIC
      • 45     CYTOO S.A.
      • 46     DAKTARI DIAGNOSTICS
      • 47     DANAHER CORPORATION
      • 48     DELTADOT
      • 49     DOLOMITE
      • 50     ELVEFLOW
      • 51     EMPIRE GENOMICS
      • 52     ENVIROLOGIX
      • 53     EPFL
      • 54     EPIGEM
      • 55     EPROGEN, INC
      • 56     EUROFINS SCIENTIFIC
      • 57     EXIQON
      • 58     FLOWJEM
      • 59     FLUIDIGM CORPORATION
      • 60     FLUIGENT
      • 61     GE HEALTHCARE
      • 62     GENETIX
      • 63     GENOMIC SOLUTIONS INC
      • 64     HELICOS BIOSCIENCES
      • 65     HELOMICS
      • 66     MIRAIBIO, INC (HITACHI GENETIC SYSTEMS)
      • 67     IBM CORPORATION
      • 68     ILLUMINA, INC
      • 69     JPT PEPTIDE TECHNOLOGIES GMBH
      • 70     LABSMITH INC
      • 71     LEUKODX
      • 72     LOBION INFORMATICS LLC
      • 73     MERCK & CO.
      • 74     MICRALYNE
      • 75     MICRO2GEN
      • 76     MICROARRAYS INC.
      • 77     MICROLIQUID
      • 78     MICRONIT MICROTECHNOLOGIES B.V.
      • 79     MICRUX TECHNOLOGIES
      • 80     MILDENDO GMBH
      • 81     MOBIDIAG
      • 82     MOLECULAR DEVICES
      • 83     NANO CELLECT BIOMEDICAL INC.
      • 84     NANOSURF AG
      • 85     OCIMUM BIOSOLUTIONS LIMITED
      • 86     ON-CHIP BIOTECHNOLOGIES CO. LIMITED
      • 87     OPTOFLUIDICS INC
      • 88     ORIGENE
      • 89     PERKINELMER
      • 90     PHADIA
      • 91     PHALANX BIOTECH GROUP
      • 92     PRECISION NANOSYSTEMS
      • 93     PROMEGA
      • 94     QIAGEN
      • 95     QUANTUMDX GROUP LTD
      • 96     RAIN DANCE TECHNOLOGIES
      • 97     RANDOX LABORATORIES LTD
      • 98     RAY BIOTECH INC.
      • 99     ROCHE APPLIED SCIENCE
      • 100     SAFEGAURD BIOSYSTEMS HOLDINGS LTD
      • 101     SAS KLEARIA
      • 102     SAVYON DIAGNOSTICS LTD
      • 103     SCANALYTICS, INC
      • 104     SCIENION AG
      • 105     SCIOMICS
      • 106     SPHERE FLUIDICS
      • 107     THERMOFISHER SCIENTIFIC
      • 108     U S BIOMAX, INC